At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27,190 enrolled
Drug / intervention
Tiotropium and Olodaterol (Tio+Olo) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness and Safety of Maintenance Treatment With Combination of Tiotropium and Olodaterol in Comparison to Maintenance Treatment With a Combination of Inhaled Corticosteroids, Long-acting β2 Agonists and Long-acting Muscarinic Antagonists in COPD Patients
In Brief
An observational study evaluating Tiotropium and Olodaterol (Tio+Olo) and Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS) for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 27,190 participants across 1 site.
Detailed Summary
To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by exacerbation risk
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartNov 2019
Primary CompletionNov 2019
First PostedDec 2019
TodayJul 2026
First PostedDec 3, 2019
Enrollment StartNov 1, 2019
Primary CompletionNov 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3 daysPosted 6.6 years ago
Interventions
Tiotropium and Olodaterol (Tio+Olo)drug
drug
Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)drug
drug